Who is sponsoring NCT02892305?

NCT02892305 is sponsored by Duke University.

What drugs are being tested in NCT02892305?

Interventions in NCT02892305: Hepatic Resection or Ablation with Pancreaticoduodenectomy.

What condition does NCT02892305 study?

NCT02892305 studies Pancreatic Neoplasms, Neoplasm Metastasis, Liver Metastases.

Is NCT02892305 still recruiting?

NCT02892305 is currently active, enrolled. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT02892305

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hepatic Resection for Metastatic Pancreatic Cancer

Active, enrolled Last updated 6 August 2025

What this trial tests

trial testing Hepatic Resection or Ablation with Pancreaticoduodenectomy in Pancreatic Neoplasms in 18 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 May 2018

Primary endpoint
17 May 2023

30 June 2027

Quick facts

Lead sponsor	Duke University
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	18
Start date	18 May 2018
Primary completion	17 May 2023
Estimated completion	30 June 2027
Sites	1 location across United States

Drugs / interventions tested

Hepatic Resection or Ablation with Pancreaticoduodenectomy

Conditions studied

Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →
Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
Liver Metastases — all drugs for Liver Metastases →

Sponsor

Duke University

Who can join

Adults 18 to 90, any sex, with Pancreatic Neoplasms or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM). We will evaluate and describe the surgical and overall outcomes of an initial cohort of subjects who undergo pancreatectomy and hepatic resection/ablation for PAC with LVHM. The end of study results will be reviewed by the Hepatiobiliary Multidisciplinary Conference (HDMC) and Surgery Audit Committee (SAC) to determine the appropriateness of adding this treatment arm for patients with oligometastatic metastatic pancreatic cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.
Pedrazzoli S. · · 2023 · cited 8× · PMID 37892599 · DOI 10.3390/jcm12206461
Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option.
Argentiero A, Calabrese A, Sciacovelli AM, Delcuratolo S, et al · · 2020 · cited 1× · PMID 33102398 · DOI 10.1155/2020/8679751
Society of Surgical Oncology SSO 2023 - International Conference on Surgical Cancer Care.
· 2023 · PMID 36879037 · DOI 10.1245/s10434-023-13332-7

Verify or expand the search:

Other recruiting trials for Pancreatic Neoplasms

Currently open trials in the same condition.

NCT07504471 — Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhib · Phase 2 · recruiting
NCT07139236 — Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06939023 — Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) · NA · recruiting
NCT06953193 — Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia · NA · recruiting

Other Duke University trials

Trials by the same sponsor.

NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02892305 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02892305.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing